- The first patient has been dosed in a Phase 1/2 clinical trial evaluating Momenta Pharmaceuticals' (NASDAQ:MNTA) M254 in healthy volunteers and in patients with immune thrombocytopenic purpura, an autoimmune disorder characterized by low blood platelets and excessive bruising and bleeding.
- The company says M254 is a hyper-sialylated immunoglobulin G engineered from pooled plasma that is more than 10 times as potent as conventional intravenous IgG.
Dosing underway in study of Momenta's engineered immunoglobulin G
Recommended For You
More Trending News
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MNTA | - | - |
Momenta Pharmaceuticals, Inc. |